comparemela.com

Latest Breaking News On - Vision therapeutics inc - Page 1 : comparemela.com

Aequus Strengthens Clinical Experience in Stargardt Disease

Aequus Strengthens Clinical Experience in Stargardt Disease
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Aequus and reVision to Collaborate on Stargardt Disease Program

Aequus and reVision to Collaborate on Stargardt Disease Program
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Aequus and reVision to Collaborate on Stargardt Disease

Aequus and reVision to Collaborate on Stargardt Disease
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Why Investment in Open Innovation Has Become So Important During the COVID-19 Pandemic

SHARE During a time where health is globally prioritized more than ever due to the COVID-19 pandemic, learning about investment in open innovation has become an important part of accessible health care. Vaccines, therapies, diagnostics and treatment regimens are now able to be developed quicker than ever with the proper incentives and resources. Kathleen Entwistle, private wealth advisor at Morgan Stanley Private Wealth Management, Paul Fehlner, cofounder and president/CEO of reVision Therapeutics, Inc., and Barbara Handelin, cofounder and CEO of Audacity Therapeutics, PBC, recently discussed with Worth how medicine is changing the future of health care. According to Handelin, Audacity Therapeutics’ main focus is to develop “as many medicines as we could for important, serious diseases using all kinds of innovation, including, and especially, the repurposing of existing drugs, and investing in the kinds of diagnostics that just will never be touched by venture capital.”

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.